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Abstract  
Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair 
defects. ERCC1 deficiency is frequently found in non-small cell lung cancer (NSCLC), making 
this DNA repair protein an attractive target for exploiting synthetic lethal approaches in this 
disease. Using unbiased proteomic and metabolic high-throughput profiling on a unique in-house 
generated isogenic model of ERCC1 deficiency, we found marked metabolic rewiring of ERCC1-
deficient populations, including decreased levels of the metabolite NAD+ and reduced expression 
of the rate-limiting NAD+ biosynthetic enzyme nicotinamide phosphoribosyltransferase 
(NAMPT). We further evidenced reduced NAMPT expression in NSCLC samples with low levels 
of ERCC1. These metabolic alterations were a primary effect of ERCC1 deficiency, and caused 
selective exquisite sensitivity to small molecule NAMPT inhibitors, both in vitro – ERCC1-
deficient cells being approximately 1000 times more sensitive – and in vivo. Using transmission 
electronic microscopy and functional metabolic studies, we found that ERCC1-deficient cells 
harbor mitochondrial defects. We propose a model where NAD+ acts as a regulator of ERCC1-
deficient NSCLC cells’ fitness. These findings open therapeutic opportunities that exploit a yet 
undescribed nuclear - mitochondrial synthetic lethal relationship in NSCLC models, and highlight 
the potential for targeting DNA repair/metabolic crosstalks for cancer therapy. 
 
Keywords: ERCC1, NAMPT, NAD+, SIRT1, tumor metabolism, synthetic lethality, nuclear-
mitochondrial crosstalk, lung cancer 
Running head: Exquisite sensitivity to NAMPT inhibitors and metabolic defects of ERCC1-
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Introduction 
Despite recent therapeutic advances, non-small cell lung cancer (NSCLC) remains the leading 
cause of cancer death (1). Novel effective therapeutic approaches for this aggressive malignancy 
are therefore urgently required. The discovery of tumor-specific molecular alterations has 
revolutionized the development of targeted approaches for cancer. For example, genetic 
dependency effects, such as oncogene addiction and synthetic lethal interactions, offer the 
potential to selectively target driver mutations or genetic deficiencies in cancer. 
Excision repair cross-complementation group 1 (ERCC1), a key player of the nucleotide excision 
repair (NER) and interstrand crosslink repair (ICL-R) pathways, is the most frequent deficient 
DNA repair protein in NSCLC (reviewed in ref. (2)). ERCC1 deficiency correlates with sensitivity 
to agents that stall DNA replication forks, such as platinum-salts and PARP inhibitors (3-5). 
However, drug resistance and/or cumulative toxicities ultimately occur, limiting drug efficacy. 
Additional therapeutic approaches targeting ERCC1-deficient cancers are thus needed. 
Many of the synthetic lethal approaches for cancer treatment have to date focused on interactions 
within DNA repair pathways, associating inhibition of DNA repair enzymes to defects in DNA 
repair related tumor suppressor genes, for example Poly(ADP-ribose) polymerase 1 (PARP1) 
inhibition in BRCA1- or BRCA2-mutant tumors (reviewed in ref. (6)). Far less emphasis has been 
placed upon inhibition of non-DNA repair processes in tumor cells with pre-existing DNA repair 
defects. Previous studies revealed that DNA damage response can directly or indirectly impact 
cellular metabolism, and that aging and defects in DNA repair systems could contribute to 
alterations in mitochondrial function and energy metabolism (7-11). Mouse models of Xeroderma 
Pigmentosum group A (XPA) and Cockayne Syndrome group B (CSB) display aberrant activation 
of the DNA repair enzymes PARPs with concomitant depletion of nicotinamide adenine 
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dinucleotide (NAD+) and mitochondrial dysfunction, which can be partly rescued by 
supplementation with NAD+ precursors (8, 9). NAD+ acts as rate-limiting cofactor for the DNA 
repair enzymes PARPs (12). PARP1, whose activation catabolizes a significant amount of NAD+ 
(7, 12), is the most abundant nuclear protein of the PARP family and serves as sensor to DNA 
damage (6). Deciphering and exploiting interactions between these two hallmarks of cancer – 
namely DNA damage response and dysregulation of cellular energetics – could therefore unravel 
mechanism-based therapeutic opportunities for targeting DNA repair defects in human 
malignancies. 
We hypothesized that ERCC1 deficiency resulted in metabolic reprogramming of cancer cells that 
in turn generated specific metabolic vulnerabilities. To explore that hypothesis, we used an 
unbiased large-scale comparative approach based on proteomic and metabolic profiling of isogenic 
NSCLC models of ERCC1-deficiency. This allowed us to identify striking metabolic differences 
between ERCC1-proficient and ERCC1-deficient NSCLC cells. Among them, decreased NAD+ 
and mitochondrial defects were associated with a profound selective sensitivity to NAD+ depletion 
induced by nicotinamide mononucleotide phosphoribosyl-transferase (NAMPT) inhibition. Data 
presented here unveil promising synthetic lethal approaches based on metabolic targeting of 
ERCC1-deficient NSCLC populations. 
 
Results 
A proteomic screen identifies NAMPT as significantly decreased in ERCC1-deficient NSCLC 
cells. In order to understand proteomic differences between ERCC1-proficient and ERCC1-
deficient cells, we performed a high throughput SILAC (Stable Isotope Labeling by Amino acids 
in Cell culture) analysis. To maximize the potential for identifying ERCC1-selective effects, we 
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used our in-house generated panel of ERCC1-isogenic cell lines, where ERCC1 had been 
inactivated by zinc finger gene targeting (5, 13). This panel, derived from the A549 NSCLC cell 
line, includes eight cell populations: one parental ERCC1-WT, one ERCC1-heterozygous (Hez), 
two ERCC1-deficient (“knock-out” – KO1 and KO2), and four “rescue” ERCC1-KO in which one 
of the four ERCC1 isoform has been stably reintroduced (isoforms 201, 202, 203 or 204, 
respectively). As previously reported, this model is representative of the clinical and biological 
characteristics associated with ERCC1-deficiency (4, 5, 13). The ERCC1-proficient parental cell 
line and one ERCC1-deficient clone were grown in culture media only differing by isotopic amino 
acids (AA) (Figure 1A): the “light” culture contained unlabeled AAs (Lys 0, Arg 0) whereas the 
“heavy” culture contained isotope-labeled AAs (Lys 8, Arg 10). After eight doubling times, 
proteins were extracted, digested, off-gel fractionated, and analyzed using liquid chromatography-
tandem mass spectrometry (LC-MS/MS). A forward and a reverse experiment, where isotope 
labeling was inverted between cell lines, were performed in parallel in order to minimize false-
positive results. This approach evidenced 45 “hits” (out of 5051 identified proteins), which were 
significantly differentially expressed between the ERCC1-WT and the ERCC1-KO cells (Figure 
1B). Among these hits, two proteins were involved in the NAD+ biosynthesis pathway: NAMPT 
(Nicotinamide Mononucleotide Phosphoribosyl-Transferase) and NNMT (Nicotinamide N-
Methyltransferase) (2- and 3.1-fold decrease in ERCC1-KO cells respectively, P<10-6) (Figure 
1B); three subunits of complex IV (cytochrome c oxidase) of the mitochondrial respiratory chain 
(COX4I1, COX5B, and COX6C) were also significantly decreased in ERCC1-KO populations 
(1.3-, 2.1- and 2.5-fold, respectively, P<0.0001).  
NAMPT catalyzes the rate-limiting step of NAD+ biosynthesis salvage pathway (Figure 1C), 
thereby playing a crucial role in the maintenance of intracellular NAD+ – an essential cofactor 
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involved in several cellular reactions, including cellular energetics and DNA repair (14, 15). 
Growing evidence indicates that NAMPT exerts oncogenic activity in the context of cancer and 
several NAMPT inhibitors have already been evaluated in early phase trials (16) – with others 
being currently developed (17). NAMPT therefore appeared to be a targetable node in ERCC1-
defective tumors and we decided to further focus on this target.  
 
Decreased NAMPT expression is found in several ERCC1-deficient non-small cell lung cancer 
models and in immunohistochemical study of lung adenocarcinomas. Because high-throughput 
experiments are prone to false positives, we validated the observed NAMPT decrease by Western 
Blot in the A549 isogenic model (Figure 2A). We then sought to extend this finding to an 
alternative ERCC1 isogenic model created using the same gene targeting procedure (ZNFs) in the 
H1975 NSCLC cell line (Figure 2B), which harbors a different genetic background (18). 
Consistent with our observations in the A549 model, NAMPT levels were significantly decreased 
in the H1975 ERCC1-heterozygous and ERCC1-KO cells. The observation of decreased NAMPT 
in the ERCC1-heterozygous populations suggested a haplo-insufficiency phenomenon. We then 
explored whether the decrease in NAMPT protein levels in ERCC1-deficient cells was a 
consequence of a transcriptional (mRNA) or post-transcriptional regulation. RT-qPCR performed 
on mRNA extracts and evaluation of bortezomib – a proteasome inhibitor – on NAMPT protein 
levels in the A549 isogenic model, evidenced that NAMPT decrease was controlled at the mRNA 
level (Figure 2C and Supplementary Figure 1). 
To address the clinical relevance of the NAMPT decrease, we assessed ERCC1 and NAMPT 
expression by immunohistochemistry on a series of 55 resected human lung adenocarcinoma 
samples (Figure 2D-E and Supplementary Figure 2). The median NAMPT staining H-score was 
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150 (standard deviation [SD] = 72) for the ERCC1-high samples (n=40), whereas it was 100 (SD 
= 60) for the ERCC1-low samples. Although some degree of overlap was observed between both 
populations, this difference was statistically significant (P = 0.014; Figure 2D).  
Collectively, these results show that, in NSCLC cellular models as well as in human 
adenocarcinoma samples, ERCC1 deficiency associates with a significant decrease in NAMPT, 
which is most likely controlled at the transcriptional level.  
 
Decreased NAMPT in ERCC1-deficient NSCLC cells leads to profound synthetic lethal 
sensitivity to NAMPT inhibition. In humans, most NAD+ is produced from nicotinamide salvage 
pathway (Figure 1C) (14). As NAMPT is the rate-limiting enzyme of the salvage pathway, its 
inhibition represents a potent way to efficiently lower cellular NAD+ levels. We hypothesized that 
inhibiting NAMPT in ERCC1-deficient cells, and consequently further reducing NAD+ levels, 
might impact cellular fitness.  
Exposure of tumor cells to FK866 (Figure 3A), a highly specific non-competitive inhibitor of 
NAMPT, revealed dramatic and profound sensitivity of ERCC1-KO cells (Figures 3B-D). FK866 
IC50 was 100 times lower in ERCC1-KO cells than in ERCC1-proficient ones in short-term assays 
(Figure 3B), and was 1000 times lower in long-term colony formation assays (Figures 3C-D). 
Interestingly, ERCC1-Hez cells were as sensitive to FK866 as ERCC1-KO cells, again suggesting 
haplo-insufficiency (Figures 3B-D). The study of cell death mechanisms showed PARP1 cleavage 
and increased Annexin V-positive populations on FK866 exposure in ERCC1-deficient cells only, 
without LC3 cleavage, suggesting that apoptosis was responsible for cell death (Figures 3E-F, 
Supplementary Figure 3) 
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Synthetic lethal sensitivity to NAMPT inhibition is a primary effect of ERCC1-deficiency. In 
order to confirm the specificity of the observed effect, we used several alternative models to 
revalidate our findings: (i) the four ERCC1-KO cell lines in which each ERCC1 isoform had been 
stably reintroduced, (ii) the alternative isogenic cell line model derived from the H1975 cell line, 
and (iii) a non-isogenic panel of NSCLC cell lines.  
Only ERCC1 isoform 202 has been shown to be responsible for ERCC1 DNA repair activity as 
well as sensitivity to platinum salts and PARP inhibitors (5, 13). The role and functionality of the 
three other isoforms are still unknown. NAMPT protein expression was only restored in the 
ERCC1-KO cell line in which isoform 202 had been stably reintroduced (Figure 4A), and remained 
unchanged upon reintroduction of the other isoforms. Consistently, isoform 202 was the only one 
able to restore FK866 resistance in rescue experiments (Figure 4B). Despite a different genetic 
background, the alternative H1975 isogenic models of ERCC1-deficiency displayed similar 
sensitivity to FK866 to the A549 models (Figure 4C). Interestingly, both ERCC1-KO and ERCC1-
Hez cell lines were again profoundly more sensitive to FK866 than their ERCC1-proficient 
counterpart – suggesting a haplo-insufficiency phenomenon that is not observed with cisplatin 
(Supplementary Figure 4A). To further extend our findings, we assessed sensitivity to FK866 in a 
non-isogenic panel that included three additional NSCLC cell lines genetically different from 
A549 and H1975 cells. NSCLC cells expressing lower ERCC1 protein levels were more sensitive 
to FK866 than the ones expressing higher ERCC1 levels (Supplementary Figure 4B-C). 
Altogether, (i) the ability of ERCC1-isoform 202 to rescue sensitivity to FK866 and (ii) the FK866 
selectivity towards ERCC1-deficient populations in multiple independent ERCC1-deficient 
models support that the sensitivity to NAMPT inhibition is directly related to ERCC1-deficiency. 
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ERCC1-NAMPT synthetic lethal relationship is related to the disruption of the NAD+ salvage 
pathway. As small molecule inhibitors have potential off-target effects, we assessed ERCC1-
deficient cells’ sensitivity to GNE-617, an alternative small molecule NAMPT inhibitor (Figure 
3A). This latter compound showed similar selectivity with regards to ERCC1-deficient cells 
(Figure 4D), supporting an on-target and class effect.  
We then evaluated the impact of the addition of nicotinamide mononucleotide (NMN) - the direct 
product of NAMPT enzymatic activity (Figure 1C) - on NAMPT inhibitor sensitivity. Addition of 
NMN to the culture media completely reversed the toxicity of the two small molecule NAMPT 
inhibitors in both isogenic models, confirming their on-target effect (Figures 4E-F; Supplementary 
Figure 4D). Further, silencing of NAMPT by siRNA showed selective toxicity towards ERCC1-
deficient populations (Figures 4G-H), thereby reinforcing the on-target characteristic of the 
observed effect. Together, these data support that the synthetic lethal relationship between ERCC1 
deficiency and NAMPT results from the concomitant disruption of ERCC1-dependent functions 
and the NAD+ recycling pathway, and indicate that minimal residual NAMPT activity is essential 
for survival of ERCC1-deficient NSCLC cells. 
 
NAMPT inhibition is exquisitely toxic to ERCC1-KO cells in vivo. To address the in vivo 
relevance of NAMPT inhibition, we implanted equal amounts of either ERCC1-WT or ERCC1-
KO cells into 6-week-old athymic nude (nu/nu) mice. Once tumors reached a minimal volume of 
100 mm3, mice were randomly allocated to FK866 or vehicle treatment (Figure 5A). FK866 
administration schedule (intra peritoneal injection twice a day, 4-days on / 3-days off) was selected 
based on previous efficacy – tolerability studies (19). Although FK866 delayed tumor growth in 
all populations, only ERCC1-KO models displayed significant difference in tumor volumes 
	 12	
between the FK866 and vehicle groups (Figures 5B-D). This effect was much more profound and 
prolonged in ERCC1-KO xenografts (Figures 5C-D), with some tumors being not palpable 
anymore after 20 to 48 days of treatment. Mice weights were similar in all experimental arms over 
the whole treatment duration, confirming adequate tolerability of this dosing schedule 
(Supplementary Figure 5A-C). These results demonstrate that NAMPT inhibition causes tumor 
shrinkage and decreased growth of established ERCC1-deficient xenografts in vivo. 
 
ERCC1-deficient cells present a characteristic metabolic profile, including alterations in the 
tricarboxylic acid (TCA) cycle and NAD+ biosynthesis pathway. The initial SILAC screen 
evidenced decreased protein expression of NAMPT, NNMT, and three subunits of the 
mitochondrial respiratory complex IV, which led us to hypothesize altered NAD+ biosynthesis 
and mitochondrial dysfunction in ERCC1-deficient cells. In order to investigate these metabolic 
disturbances, we performed a large scale metabolic profiling of two ERCC1-KO clones, the 
ERCC1-Hez cell line and the ERCC1-WT cell line from our A549 isogenic model, using LC-
MS/MS, GC-MS/MS (Gas Chromatography – tandem Mass Spectrometry) and LC-QTOF 
(Quadrupole Time-of-Flight). Combined results from these three approaches (see methods) 
resulted in a final dataset of 1947 metabolites defined by high-resolution m/z identification, 159 
of which were kept for further analysis. These 159 metabolites had previously been validated by 
the metabolomics platform (“annotated” panel) and were annotated as level 1 according to the 
recommendations of the Metabolomics Society for metabolite annotation 
(http://www.gigasciencejournal.com/content/pdf/2047-217X-2-13.pdf).  
Unsupervised clustering of the 159 annotated metabolites showed that all ERCC1-deficient cells 
lines clustered together and according to their ERCC1 status, away from their ERCC1-proficient 
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counterpart (Figure 6A). Of note, this unsupervised clustering based on metabolites recapitulated 
the clustering based on ERCC1 expression, thereby supporting a link between genetic and 
metabolic abnormalities. The heterozygous cell line metabolic profile was closer to the ERCC1-
KO clones’ metabolic profile than to the one of the ERCC1-WT parental cell line, in agreement 
with the haplo-insufficiency previously observed for NAMPT expression and NAMPT inhibitors 
sensitivity (Figures 2A-B, 3B-C, 4; Supplementary Figures 2, 4). This metabolic profiling 
evidenced a significantly different expression of several metabolites from the NAD+ biosynthesis 
pathway (Figure 6B; Supplementary Figure 6A); NAD+, NADH, NADP+, NADPH, nicotinamide 
and nicotinamide mononucleotide were significantly diminished (1.5-2.5 fold) in ERCC1-KO 
models as compared to ERCC1-WT cells (Figure 6B; Supplementary Figure 6A). This was 
accompanied by changes in several metabolites from the TCA cycle. Citrate/isocitrate, 2-
oxoglutarate were significantly decreased (all p < 0.05), while succinate was significantly 
increased in ERCC1-deficient cell lines (p < 0.05) (Supplementary Figure 6B-C). Assessment of 
the succinate dehydrogenase inhibition did not alter fumarate and succinate levels, thereby 
suggesting that the underlying mechanism might not be a flow reversal from fumarate to succinate 
in the TCA (Supplementary Figure 6D). Several fatty acid-derived acylcarnitines were 
significantly increased in ERCC1-deficient cells (all p < 0.05) (Supplementary Figure 6E), in a 
pattern encountered when beta-oxidation is disrupted. Combined alteration of TCA and beta-
oxidation are expected consequences of defective oxidative phosphorylation. Altogether, the 
metabolic data supported that ERCC1 deficiency was associated with a significant metabolic 
rewiring affecting NAD+ biosynthesis and oxidative phosphorylation in NSCLC cells. 
 
FK866 exposure dramatically exacerbates baseline metabolic differences between ERCC1-
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proficient and ERCC1-deficient models. In order to assess whether the FK866 selective effect on 
ERCC1-deficient models was driven by metabolic changes, we investigated the effects of FK866 
at a non-lethal dose on large scale metabolic profiling. After 24 hours of drug exposure, cells were 
lysed and metabolites were extracted for GC-MS/MS and LC-MS/MS + LC-QTOF analyses. As 
expected, FK866 exposure caused a profound decrease in NAD+, NADH, NADP, NADPH and 
nicotinamide levels in all cell lines (Figure 6B). This effect was strikingly more marked in ERCC1-
deficient populations (ERCC1-KO and ERCC1-Hez) than in their ERCC1-proficient counterparts, 
with metabolites from the NAD+ biosynthesis pathway becoming among the most differentially 
expressed on FK866 exposure (Supplementary Figures 6A and 6F). In ERCC1-deficient cells 
exposed to FK866, NAD+ level was down to an eight-fold decrease, while a two-fold decrease 
only was observed in the ERCC1-WT population (Figure 6B). Disturbances among intermediates 
of the TCA cycle (isocitrate, 2-oxoglutaric acid, succinic acid and fumaric acid) were exclusively 
observed in the ERCC1-deficient cells (Supplementary Figure 6B-C). ATP/ADP (adenosine 
diphosphate) and ADP/AMP (adenosine monophosphate) ratios, two major sensors of energetic 
equilibrium, were markedly decreased (Supplementary Figure 6G) whereas ATP levels were 
conserved, suggesting the activation of alternative reactions to maintain cellular ATP homeostasis. 
These results show that FK866 treatment exacerbates NAD+ depletion as well as its associated 
consequences on TCA and bioenergetics. 
 
ERCC1-deficient cells display abnormal mitochondrial structure, decreased respiratory 
capacity and increased glycolysis, but no elevated reactive oxygen species (ROS) levels. 
Alterations found in TCA cycle and beta-oxidation, two major mitochondrial pathways, led us to 
analyze mitochondrial ultrastructure by electron microscopy. ERCC1-Hez and ERCC1-KO cells 
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displayed abnormal mitochondrial ultrastructure associating mitochondrial swelling (a mark of 
mitochondrial dysfunction (20)), increased mitochondrial area (mean area 0,86 µm² in the ERCC1-
WT cells versus 1,28 µm² in the ERCC1-KO cells, P=0.0002) and abnormal cristae (including 
distortion, stacking, or whirling) (Figures 7A-B). 
We further sought to investigate the mitochondrial function by measuring the respiration rate using 
Seahorse XF technology (Seahorse Bioscience®), which allows concomitant analysis of the 
glycolysis rate.  These analyses evidenced impaired mitochondrial respiration in ERCC1-deficient 
cells, which displayed significantly lower basal oxygen consumption rate (OCR) than ERCC1-WT 
cells (Figure 7C). Conversely, the extracellular acidification rate (ECAR) – indicator of glycolysis 
– was markedly higher in the ERCC1-Hez and ERCC1-KO cells (Figure 7D). OCR under 
oligomycin (an inhibitor of ATP synthase), which measures respiration not producing ATP, was 
similar in all cell lines. This was also the case for the OCR under antimycin A (an inhibitor of 
respiratory complex III), which measures the non-respiratory oxygen consumption. In contrast, the 
maximal respiration rate under the maximal Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) 
dose appeared higher in ERCC1-WT and ERCC1-Hez than in ERCC1-KO cells, suggesting a 
higher respiratory complex content in the two former populations than in the latter one. As only 
two CCCP concentration could be evaluated by Seahorse®, we used high-resolution respirometry 
with Oroboros to extend CCCP titration. This complementary approach confirmed the decreased 
basal respiration and impaired maximal respiration in ERCC1-deficient populations 
(Supplementary Figure 7A-B, all P<0.001).  
Because redox homeostasis is intimately tied to DNA repair and mitochondrial integrity, we 
assessed whether reactive oxygen species were elevated in ERCC1-deficient cells, which could 
influence their response to NAMPT inhibition. We used six complementary approaches which 
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allowed us to evaluate: (i) intra-cellular ROS production (Dihydroethidium), (ii) extra-cellular 
ROS production (Amplex/HRP assay), (iii) oxidative adducts (carbonyls and hydroxynonenal) and 
(iv) the protein level of anti-oxidant enzymes (SOD1, SOD2 and PRDX3). All experiments 
indicated that ERCC1-deficient cells did not harbor any increased ROS levels (Supplementary 
Figure 8A-G). Altogether, these results support that ERCC1 deficiency associates with severe 
defects in mitochondrial structure and respiration in NSCLC models.  
 
Loss of ERCC1 associates with defects in mitochondrial respiratory chain complex IV. Because 
the SILAC screen originally identified a significant decrease in the expression of three subunits of 
the mitochondrial respiratory chain complex IV, we hypothesized that the respiratory defect 
observed in ERCC1-deficient cells might be related to defects in components of the mitochondrial 
electron transfer chain (ETC). We confirmed by western blot the decrease of COX2 and COX4 
subunits (Figures 8A-B). Because mitochondrial complexes protein expression is not necessarily 
correlated to activity, we further measured the enzymatic activity of complex IV using respiratory 
chain spectrophotometric assay (21). This showed a significant decrease in mitochondrial complex 
IV activity in ERCC1-KO cells (Figure 8C), which was rescued upon reintroduction of the 
functional ERCC1 isoform (Figure 8D). We used spectrophotometry to measure the enzymatic 
activities of mitochondrial complexes II, II+III and citrate synthase activity; this did not allow us 
to evidence significant differences between ERCC1-proficient and ERCC1-deficient cells (Figure 
8C). We further assessed the mitochondrial DNA (mtDNA) content in our A549 isogenic model 
using quantitative PCR. This evidenced a decrease in mtDNA copy number in ERCC1-KO 
populations, which was rescued upon reintroduction of the functional ERCC1 isoform 
(Supplementary Figure 9A). 
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Sirtuin-1 (SIRT1) is an NAD+-dependent nuclear deacetylase which is involved in the regulation 
of mitochondrial content (12) (22). Lower SIRT1 activity and altered mitochondrial metabolism 
or biogenesis have been associated with several pathological processes, including syndromes 
caused by defects in DNA repair proteins involved in NER (7). ERCC1-deficient cells displayed 
decreased SIRT1 expression on Western Blot (Figure 8E). Although decreased SIRT1 expression 
may not confer decreased SIRT1 activity, this might suggest that the NAD+/SIRT1 axis is 
downregulated in ERCC1-deficient cells, which would result in altered nuclear-mitochondrial 
signaling. 
 
Acute ERCC1 defect causes increased ADP-ribosylation, whereas chronic ERCC1 defect is 
associated with reduced NAD+ availability and decreased ADP-ribosylation capacities. Because 
ERCC1-deficient models had been chronically defective in ERCC1, we sought to evaluate the 
effects of the acute loss of ERCC1. ERCC1 silencing by siRNA was accompanied by increased 
ADP-ribosylation levels upon H2O2 exposure (Figure 9A), suggesting that PARP1 activation 
compensates for ERCC1 loss when DNA is damaged. Strikingly, we repeatedly observed an initial 
increase in NAMPT expression accompanying ERCC1 silencing, potentially indicating a cellular 
regulation loop aiming at maintaining the homeostasis of NAD+ levels (Figure 9B). To mimic a 
progressive loss of ERCC1 over time, we performed several sequential cellular infections with 
viral particles encoding ERCC1 shRNA in the A549 cell line. This showed gradual loss of ERCC1 
on repeated infections, which was associated with gradual decrease in NAMPT expression (Figure 
9C). We went on to assess DNA repair capabilities of ERCC1-deficient cells. As previously 
published (5), these cells do not have defects in RAD51 loading. We observed decreased ADP-
ribosylation in the ERCC1-deficient isogenic models upon H2O2 exposure, which was rescued by 
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the addition of NMN to the medium (Figures 9D and 9E), suggesting that low NAD+ levels limit 
PARP1 activation in cells with chronic ERCC1 deficiency. 
We then sought to explore why NAMPT expression was, contra-intuitively, decreased in ERCC1-
deficient cells that present low NAD+ levels. SIRT1 has previously been described as being able 
to regulate NAMPT levels (23). Because our previous experiments suggested decreased SIRT1 
activity, we assessed the ability of STR2104, a SIRT1 activator, to restore NAMPT expression. 
Exposure to STR2104 at non-lethal concentrations allowed a dose-dependent increase of NAMPT 
expression, both at the mRNA and protein levels, consistent with a regulation at the mRNA level 
(Figures 9F-G). Collectively, these results suggest that NAD+ levels are key in regulating the DNA 
damage response in ERCC1-deficient models.  
 
A model for ERCC1-deficient NSCLC sensitivity to NAMPT inhibitors in which NAD+ is the 
central sensor of ERCC1-deficient models’ fitness. One proposed model that is consistent with 
the data is the following (Figure 10): (i) acute loss of ERCC1 induces dependency upon PARP1 
activation for the repair of DNA lesions. Short-term PARP1 activation is beneficial for maintaining 
genomic stability, but results in a burst of NAD+ consumption. In this scenario of transient and 
acute response, cellular responses to compensate NAD+ overconsumption are triggered, including 
NAMPT upregulation. This allows NAD+ level to be maintained above a critical threshold; (ii) 
chronic ERCC1-deficiency induces chronic PARP1 activation, which is eventually deleterious as 
it overcomes the cellular NAD+ self-replenishment capacities. This associates with metabolic 
defects including decreased NAD+ and NAMPT levels, as well as alterations in the mitochondrial 
respiratory chain. In this scenario, NAD+ levels are low but remain above a critical threshold 
allowing ERCC1-deficient cells to survive and proliferate. (iii) Treatment with NAMPT inhibitors 
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block the NAD+ recycling pathway and cause an acute drop in NAD+ levels. In ERCC1-proficient 
cells, NAD+ levels remain above a critical threshold compatible with cell survival. In ERCC1-
deficient cells, this acute NAD+ drop outstrips the cellular NAD+ replenishment capacities and 
decompensates a fragile equilibrium: NAD+ levels drop below a threshold compatible with cell 
survival, which triggers cell death. In this model, NAMPT and ERCC1 are synthetic lethal, as the 
combination of ERCC1-deficiency to NAMPT inhibition causes cell death, whereas each 
perturbation in isolation (i.e. ERCC1-deficiency or NAMPT inhibition) does not.  
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Discussion 
Innovative approaches are urgently needed for NSCLC, which remains the leading cause of cancer 
death worldwide despite several recent progresses brought by targeted therapy and immune 
checkpoint blockers (1). Here, we report a link between ERCC1-deficiency and specific metabolic 
abnormalities (including a profound deficit in NAD+ biosynthesis and mitochondrial defects), 
resulting in dramatic sensitivity to NAMPT inhibitors. Using a unique in-house generated model 
of ERCC1-deficiency in NSCLC cell lines (4, 5, 13), we demonstrate that, in vitro and in vivo, 
ERCC1-deficient populations are strikingly sensitive to NAMPT inhibitors and that this exquisite 
sensitivity is a primary effect of ERCC1-deficiency. These findings represent an innovative 
therapeutic approach for NSCLC. Furthermore, we show that ERCC1-deficient populations 
display significant mitochondrial alterations, including ultrastructural abnormalities as well as 
altered TCA cycle and respiratory defects. We propose a model where NAMPT and NAD+ 
decrease provide a link between nuclear ERCC1-deficiency, mitochondrial defects and associated 
metabolic abnormalities.  
To our knowledge, we believe that this is the first description of a synthetic lethal relationship 
between the nuclear DNA repair protein ERCC1 and energetic metabolism. Of note, the magnitude 
of the observed effect (1/1000 therapeutic window in IC50 between ERCC1-WT and ERCC1-
deficient cells) is similar to that observed with PARP inhibitors in BRCA-deficient populations 
(24), thereby opening promising therapeutic opportunities. Most importantly, ERCC1-
heterozygous cell line consistently behaved similarly to ERCC1-KO models, rather than similarly 
to ERCC1-proficient cells. This haplo-insufficiency phenomenon was observed for NAMPT 
inhibitors sensitivity, metabolic profiling and mitochondrial functions but not for platinum 
sensitivity (Supplementary Figures 4A-B). This is of tremendous importance for clinical 
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applications because tumors often express low or minimal ERCC1 levels, which limits the efficacy 
of platinum salts and favors emergence of secondary resistance (4, 13). NAMPT inhibitors, either 
alone or in combination with drugs that show efficacy in ERCC1-deficient populations such as 
platinum salts or PARP inhibitors (5, 25), could therefore represent an interesting and innovative 
therapeutic approach. 
Mitochondrial dysfunction is a common feature in cell degeneration and aging (22, 26). It has also 
been associated with diseases resulting from DNA repair defects, in particular those associated 
with dysfunction of the NER proteins – including Cockayne Syndrome and Xeroderma 
Pigmentosum. In humans, mutations in ERCC1 results in severe developmental defects at birth 
and premature death (27). Mouse models of ERCC1 deficiency display severe progeroid syndrome 
associated with progressive neurodegeneration, fat loss and endocrine defects (28). To our 
knowledge, mitochondrial dysfunction has not been described so far in patients with ERCC1 
deficiency. Our observations show that ERCC1 deficiency associates with alterations in 
mitochondrial metabolism and NAD+ recycling in NSCLC models. Of note, our data were 
generated on a panel of tumor cell lines; it is possible that tumor-specific alterations such 
as TP53 mutations – which have been shown to influence cellular metabolism – are present in 
some of them. The phenotype observed in our study may therefore be distinct in non-tumor primary 
cells. The association of NAD+ depletion, decreased SIRT1 activity and mitochondrial 
disturbances has recently been reported in several NER-deficient preclinical and patient-derived 
models – including CSA-, CSB-, XPA- and XPD-deficient models (7-9) – as well as ATM-
deficient models (11) where it has been linked to nucleus to mitochondria (NM) signaling. 
Decreased NAMPT and NAD+ depletion (29-31), which may result in decreased SIRT1 activity 
(9, 32), loss of mitochondrial homeostasis and hypersensitivity to NAMPT inhibitors (33), have 
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also been reported in circumstances of increased genotoxic stress. To our knowledge, it has not 
yet been reported in ERCC1 defects in vivo nor in ERCC1-deficient cancer cells. We therefore 
believe that our findings are novel, but are in line with several previous observations in non-
cancerous models with alternative NER defects.  
Although all our observations are consistent with the proposed model (Figure 10) and with 
previous literature data derived from other DNA repair deficiencies, alternative mechanistic 
explanations might be considered. Redox homeostasis is intimately linked to DNA repair and 
increased ROS might have rendered cells more sensitive to NAMPT inhibitors. However, we did 
not observe elevated ROS levels in ERCC1-deficient cells (Supplementary Figure 8). A role for 
ERCC1 in the repair of mtDNA lesions and maintenance of mtDNA genome integrity could also 
be hypothesized, even though NER is traditionally the only DNA repair pathway absent from 
mammalian mitochondria (34). Whether ERCC1 is involved in the resolution of specific structures 
during mtDNA replication or decatenation might also warrant further investigation. Moreover, 
reliable assessment of ERCC1 functionality in tumors has been proven to be challenging, notably 
because of the presence of several closely related isoforms, which precludes their efficient 
distinction with the currently available technologies (4). In that context, integrating a metabolic or 
mitochondrial hallmark as an additional surrogate biomarker of ERCC1 functionality, alongside 
the evaluation of ERCC1 expression, might be considered. The significant correlation observed on 
our series of 55 lung adenocarcinoma cases between ERCC1 and NAMPT IHC staining reinforces 
this hypothesis. 
ERCC1 plays a key role in stabilizing XPF and enhancing its endonuclease activity. Although the 
heterodimer is a key player of the NER pathway (35, 36), it also has additional roles in the 
interstrand crosslink repair and double-strand break repair pathways (37, 38). As most ERCC1 
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functions have been linked to XPF endonuclease activity - which has also been reported as a 
biomarker in some tumor types (37, 38) - the conclusions from this work might be applicable to 
XPF-deficient malignancies as well. Recent studies reported that ERCC1 also possesses XPF-
independent functions (39, 40). The persistence of normal XPF levels and cisplatin resistance in 
the ERCC1-Hez cell lines (4, 5, 13) contrasted with the significant NAMPT decrease and NAMPT 
small molecule inhibitors sensitivity observed in this latter population. Complete ERCC1-
deficiency is thought to be embryonic lethal in humans and only three ERCC1-deficient patients 
have been described so far (27, 41). This contrasts with the higher frequency of patients suffering 
from NER-associated disorders, and highlights that ERCC1-deficiency in humans leads to a much 
more severe phenotype (27). Whether these metabolic deficiencies result from an XPF-
independent function of ERCC1 might be hypothesized (39, 40). 
There is growing interest in exploiting metabolic defects and mitochondrial dysfunction to 
selectively induce cancer cell death. In this context, several novel NAMPT inhibitors are currently 
being developed (e.g. OT-82, LSN3154567 and KPT-9274). FK866 (APO866) has been proven 
tolerable at active doses in a phase 1 trial, although dose-escalation was limited by 
thrombocytopenia (16). Our findings indicate that ERCC1-deficient tumors may respond to 
NAMPT inhibitors at lower doses than their ERCC1-proficient counterparts, which may enable 
reaching antitumor activity whilst avoiding excessive toxicities in selected populations thanks to 
a favorable therapeutic window. In addition, by analogy with the folate rescue used for high-dose 
methotrexate administration, whether the tolerability of these drugs might be improved by adding 
sequential vitamin B3 or nicotinamide mononucleotide administration (14, 19) might deserve 
clinical evaluation. Similarly, alternative schedules, using more frequent administration at lower 
doses, might be worth exploring in order to achieve similar drug exposure and avoid the peak-
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related dose-limiting toxicity. In this context, clinical trials currently evaluating NAMPT inhibitors 
may benefit from dedicated designs that would associate a dose-escalation phase exploring several 
schedules of administration – potentially including a vitamin B3-based rescue – to a dose-
expansion phase in appropriately molecularly selected patients, including patients with ERCC1-
deficient malignancies. 
In summary, we have evidenced a synthetic lethal relationship between ERCC1-deficiency and 
NAMPT inhibition in NSCLC models. These findings represent promising therapeutic 
opportunities that exploit a nucleus to mitochondria crosstalk. Considering the current 
development of several NAMPT inhibitors, we hope that these findings will rapidly translate into 
clinical evaluation through early phase trials performed in appropriately molecularly selected 
populations. 
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Material and Methods 
Cell lines. WT A549 and H1975 cells were purchased from the American Type Culture Collection 
(ATCC®). A549/H1975 ERCC1-deficient cells (denoted ‘ERCC1-Hez’, ‘-KO1’ and ‘-KO2’ for 
simplicity) and rescue clones (‘ERCC1-KO + isof 201’, ‘-202’, ‘-203’, ‘-204’) were generated as 
described previously (13). Cells lines were grown in DMEM (A549) or RPMI (H1975) (Gibco®) 
supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO2 at 37 
°C. All cell lines were tested for the absence of mycoplasma.  
 
Viability assays. For short-term viability assays, cells were plated in 96-well plates and treated 
the following day for 5 days. Cell viability was assessed using the luminescent CellTiter-Glo® 
reagent (Promega®) according to the manufacturer’s protocol. Luminescence was measured using 
the Victor X4 Multilabel plate reader (Perkin Elmer®). Dose-response curves and IC50 were 
generated using Prism 6 (GraphPad Software®) after Log transformation of the data. Curves were 
extrapolated using non-linear regression with four parameter logistic regression fitting on 
triplicates from survival fractions of at least three independent experiments, following the model: 
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope). For colony formation survival 
assay, cells were seeded in 6-well plates at 500-1500 cells/ well and treated the following day. 
Drug- or vehicle-containing media was replenished twice weekly for 10-14 days. Cells were fixed 
and stained with 0.5% crystal violet solution in 25% methanol. Viability was assessed by colony 
counting. For both short-term viability assays and colony formation survival assay, surviving 
fraction (SF) for each X concentration were calculated as SF = mean viability in treated sample at 
concentration X/mean viability of untreated samples (vehicle). 
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Antibodies. ERCC1 (FL-297) and HSC70 (B-6) antibodies were purchased from Santa Cruz®. 
NAMPT (14A.5) antibody was purchased from EMD Millipore®. SIRT1 (19A7AB4), COX4 
(20E8C12), PRDX3 (EPR8115), and HSP60 (ab46798) antibodies were purchased from Abcam®. 
β-actin (A1978). SOD1 (HPA001401), SOD2 (HPA001814), DHE (D7008) and β-tubulin (T8328-
100UL) antibodies were purchased from Sigma-Aldrich®. Anti-COX2 and -HNE antibodies were 
kindly provided by Dr. Anne Lombes, and were previously described (42, 43). DNP were 
measured using the OxyBlot Protein Oxidation Detection Kit S7150 (EMD Millipore®). 
 
Stable isotope labeling by amino acids in cell culture (SILAC). Cells were grown in SILAC 
DMEM supplemented with either isotope-labeled (Lys 8, Arg 10) or unlabeled amino acids for 
eight doubling times. Peptides were extracted as described in the Supplementary Material and 
Methods section. Reversed phase chromatography was performed using an HP1200 platform 
(Agilent®, Wokingham, UK).  
 
Metabolomic profiling. Cells were seeded in 6-well plates in DMEM supplemented with 10% 
FBS; vehicle or FK866 was added when they reached 80% of confluence and in an exponential 
growth phase. After 24 hours of vehicle/drug exposure, cells were 2sec rinsed with cold milliQ-
grade water, and were lysed by scrapping in 500µl of cold methanol/water (9/1, v/v, -20°C) 
containing internal standards. Lysates of 2 replicates were combined in microcentrifuge tubes and 
cold chloroform (100µl, -20°C) was added before 30sec vortexing and final centrifugation at 
15000rpm for 10min at +4 °C. Supernatant was collected and evaporated using a pneumatically-
assisted concentrator (Techne DB3) at 40°C. On day of chemical analysis, 300µl of methanol were 
added to the dried extract and the solution was equally split for GC-MS/MS analysis, and LC-
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MS/MS + LC-QTOF analyses. Metabolomics protocols were run as described previously (44). 
Reversal of flow to succinate from fumarate was addressed using succinate, fumarate and 
methylmalonic acid measurement by GC-MS/MS after 24h of treatment with vehicle or the 
succinate dehydrogenase inhibitor methylmalonic acid (2 mM, a dose which did not impacted cell 
growth nor survival in vitro), as described in (45). Further details on metabolic analysis are 
provided in Supplementary Material and Methods.  
 
Transmission electron microscopy. One million cells were fixed in 2% glutaraldehyde in 0.1 M 
phosphate buffer for 1h at 4°C, collected by scraping, centrifuged and post-fixed in 2 % osmium 
tetroxide. Following ethanol dehydration, cell pellets were embedded in Epon™ 812. Ultrathin 
sections were stained with standard uranyl acetate and lead citrate prior to observation with a 
Tecnai 12 electron microscope (FEI®, Eindhoven, the Netherlands). Digital images were taken 
with a SISMegaviewIII charge-coupled device camera (Olympus®, Tokyo, Japan). 
 
Subcutaneous xenografts and drug treatment. Two million of either A549 ERCC1-WT or 
ERCC1-KO cells were injected subcutaneously in the flank of 6-week-old athymic nude (nu/nu) 
mice (Charles River Laboratories, France) (n = 8 mice per group). Mice carrying 100mm3 
subcutaneous tumors were randomized to receive 30mg/kg/day FK866 (Sigma-Aldrich®) or 
vehicle (30% PEG, 5% Tween 80, Dexrose 5% in water) by intra peritoneal injection twice-daily, 
4 days on/3days off for 6 weeks. Tumor diameters were measured by the same experimented 
technician with digital caliper and tumor volumes estimated using the formula: 0.5 x length x 
width2. Body-weights were monitored twice weekly. Mice were sacrificed when tumors in the 
control group reached the maximal allowed size.  
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siRNA and shRNA. For siRNA experiments, WT were reverse-transfected with Lipofectamine 
RNA iMAX (Life Technologies®) as indicated by the manufacturer, using non-targeting siRNA 
(D-001206-13-05, Dharmacon®), siERCC1 (LU-006311-00-0002, GE Healthcare®) and 
siNAMT (M-004581-01, Dharmacon®). For shRNA experiments, HEK293T cells were 
transfected with lentiviral plasmids encoding ERCC1 shRNA (pLOK.1, REF RHS4533-EG2067) 
and packaging vectors (pCMV-R8.74 and pMD2G, http://www.addgene.org/) in order to produce 
lentiviral particles. After harvesting and concentration of lentiviral particles, A549 cells were 
infected with shERCC1-encoding particles by adding lentiviral particles in the culture media. 
Puromycin was added after 48h, in order to select infected clones. Three cycles of infection were 
realized in A549 cells each 10-15 days apart, followed by puromycin selection. 
 
ADP-ribosylation. Levels of ADP-ribosylation were measured by indirect immunofluorescence 
as described in (46). Cells were incubated overnight with drug-free media, olaparib 1uM and/or 
NMN 100uM. Olaparib, a PARP1/2 inhibitor that blocks DNA PARylation reactions, was used as 
a negative control. Cells were subsequently exposed to 1mM H2O2 for 10 min and fixed with ice-
cold methanol. ADP-ribose levels were quantified by high-throughput imaging (Operetta, Perkin 
Elmer®), using the anti-pan-ADP-ribose binding reagent (H10 monoclonal antibody 4335-AMC-
050, Trevigen®). The nuclear ADP-ribose levels of treated cells were plotted vs the levels measure 
in untreated cells. 
 
Study approval. All in vivo studies were approved by the local Ethical Committee of University 
Paris-Sud no. 26 (authorized project no. 2012-083). 
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Statistics. The number of samples, experimental repeats and details on statistical tests are indicated 
in the relevant figure legends. Adjusted P values were calculated using Prism 6, GraphPad 
Software®, and considered significant when inferior to 0.05. For metabolomics analyses, 
difference in metabolites were considered significant when FDR was inferior to 0.1. Where 
applicable, the means of population averages from multiple independent experiments (± SD or 
SEM) are indicated. The in vivo experiments were randomized. No samples/animals were omitted 
from data analyses. 
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Supplementary Material and Methods 
Protein extraction for immunoblotting. Proteins were extracted in lysis RIPA buffer (50 mM 
Tris, 150 mM NaCl, 5 mM EDTA, 0.5% sodium deoxycholic acid, 0.5% NP-40, 0.1% SDS) 
supplemented with protease inhibitor cocktail (Roche Molecular®). For the oxyblot procedure, 
samples were prepared in RIPA buffer with 50 mM DTT and 1 mM PMSF. Proteins were 
incubated with 2,4-dinitrophenylhydrazine (DNPH) to form the 2,4-dinitrophenyl (DNP) 
hydrazone derivatives. For Hydroxynonenal (HNE) quantification, samples were prepared using 
Laemli. 
 
Protein extraction for SILAC. Cells were grown in SILAC DMEM supplemented with either 
isotope-labeled (Lys 8, Arg 10) or unlabeled amino acids for eight doubling times. After protein 
extraction and quantification, equal concentration of labeled and unlabeled cells were mixed (1mL 
of lysate, equivalent 1-15 mg total protein) with 8 mL of UA buffer and load into an Amicon Ultra 
15 Ultracel 30k device, with a 1:8 lysis buffer to UA ratio. After concentrating twice at 4000g for 
30 min in 10 mL of UA, samples were incubated in darkness in 2mL of IAA at RT for 30 min, 
prior to 15 min centrifugation (4000g). After further concentration in UA, samples were washed 
twice 10 mL ABC. The filter was put onto a new tube and trypsin was added (1:100 of the lysate 
amount) in 1 mL of ABC. Digestion was conducted overnight at 37°C in a wet chamber. Peptides 
were collected by centrifugation (15 min), prior to adding 0.5 mL of ABC and spinning for 15 
min, followed by adding 0.5ml of 20% Acetonitrile in ABC. Extracts were acidified and desalted 
on a C18 cartridge (Sep-Pak), prior to off-gel isoelectric focusing using a 3100 Off-Gel 
Fractionator® (Agilent Technologies).  
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SILAC proteomic analysis. Twenty percent of each sample was analyzed as a 6µl injection, 
including a known spiked concentration of a three- peptide mixture QC sample spike. Peptides 
were resolved on a 75µm I.D. 15 cm C18 packed emitter column (3µm particle size; NIKKYO 
TECHNOS CO., LTD, Tokyo, Japan) over 120 min (SET 1 (runs 1 and 2 only) or 90min using a 
non-linear gradient of 96:4 to 50:50 buffer A:B (buffer A: 2% acetonitrile / 0.1% formic acid; 
buffer B: 80% acetonitrile / 0.1% formic acid) at 250nl/min. Peptides were ionized by electrospray 
ionization using 1.8kV applied immediately pre-column via a microtee built into the nanospray 
source. Sample was infused into an LTQ Velos Orbitrap mass spectrometer® (Thermo Fisher 
Scientific, Hemel Hempstead, UK) directly from the end of the tapered tip silica column (6-8 µm 
exit bore). The ion transfer tube was heated to 200°C and the S-lens set to 60%. MS/MS were 
acquired using data dependent acquisition based on a full 30,000 resolution FT-MS scan with 
preview mode disabled and internal lock mass calibration against the polysiloxane ion at 
445.120025 m/z. The top 20 most intense ions were fragmented by collision-induced dissociation 
and analyzed using normal ion trap scans. For sample set 2, the top 10 ions were also fragmented 
and analyzed using enhanced ion trap scans. Automatic gain control was set to 1,000,000 for FT-
MS and 30,000 for IT-MS/MS, full FT-MS maximum inject time was 500ms and normalized 
collision energy was set to 35% with an activation time of 10ms. Wideband activation was used to 
co-fragment precursor ions undergoing neutral loss of up to -20 m/z from the parent ion, including 
loss of water/ammonia. MS/MS was acquired for selected precursor ions with a single repeat count 
followed by dynamic exclusion with a 10ppm mass window for 60s (120 min gradient) (SET 1 
only) or 45s (90 min gradient) based on a maximal exclusion list of 500 entries. 
 
Metabolomic analysis. Prior to LC-MS/MS, pure standard of NMN was infused to optimize the 
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MRM transitions enabling its quantification together with 14 other metabolites: Q1=335.1 and 
Q3=123.1 with the fragmentor and the collision energy set at 100eV and 20eV. Profiles generated 
by the three methods were combined in the statistical environment R (http://www.R-project.org/) 
for data processing, peak annotation, data reduction and statistical treatment. After quality control 
checks and the exclusion of redundant metabolites, the final dataset comprises 1947 features that 
can be classified according to the recommendations of the Metabolomics Society for metabolite 
annotation (http://www.gigasciencejournal.com/content/pdf/2047-217X-2-13.pdf) as follows: 159 
as level 1, 238 as level 2 and 1550 as level 4. In the article, reporting and interpretation of the 
metabolomics profiles were only presented for the 159 level 1 features: 70 were obtained by 
metabolomics open profiling and 10 and 79 quantified by targeted LC-MS/MS and GC-MS/MS 
methods. All statistical analyses and data representation were performed on pre-processed, log2-
transformed and imputed data (47) and reported as such without back-transformation.  Moderated 
statistics were used for differential analysis (48). Levels of significance were denoted as p-values 
when in their raw form or as FDR when adjusted according to Benjamini and Hochberg (49) to 
control the false discovery rate (FDR).  
 
Respiration analyses. For Seahorse technique, proliferating A549 ERCC1-WT, ERCC1-Hez and 
ERCC1-KO cells were seeded in Seahorse XF-96 cell culture microplates in six replicates at 
20,000 cells/well. After 24h, cells were washed with unbuffered XF Assay Medium (pH 7.4, 25 
mM glucose) 1h prior to measurement. Indices of glycolysis and mitochondrial function were 
measured after sequential injections of oligomycin (1µg/ml final), CCCP (first 0,25 µM then 0,50 
µM) and antimycin A (1µg/ml). For high-resolution respirometry with the Oroboros "O2k" 
instrument (www.oroboros.at/), cells were suspended in culture medium. Respiration at 37°C was 
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measured in the basal state and after successive addition of 1 µg/mL oligomycin once, 1,25 µM 
CCCP four times (until reaching maximal respiration at a final 5 µM CCCP), and 1 mM potassium 
cyanide once. Oxygen consumption rates were calculated by Datlab 4® software and normalized 
to the number of cell/ml. Experiments were performed in duplicates. In both cases, the respiration 
linked to ATP production was calculated as the difference in oxygen consumption before and after 
injection of oligomycin. The maximal respiratory capacity was determined by subtracting the non-
respiratory oxygen consumption (under cyanide) from the maximal oxygen consumption obtained 
with CCCP.  
 
Gene expression and mtDNA content analysis by qPCR. For NAMPT gene expression analysis, 
cDNA was synthetized using the Roche® Transcription First Strand cDNA Synthesis 
(04379012001) after RNA extraction using the QIAGEN® RNeasy Micro kit (74004), according 
to the manufacturer’s protocol. Real-time PCR amplification was performed on 200 ng of total 
cDNA using the ViiA™ 7 Real-Time PCR System (Applied Biosystems) and the Taqman® Gene 
Expression Assay (4440038) according to the manufacturer’s protocol. NAMPT probe was 
purchased from ThermoFisher Scientific® (Hs00237184_m1). GAPDH (Hs03929097_g1) and 
Beta-2-microglobulin (B2M) (Hs99999907_m1) were used as endogenous reference. 
Quantification of mtDNA was performed as described (10). Real-time PCR amplification was 
performed on 200 pg of total DNA using the ViiA™ 7 Real-Time PCR System (Applied 
Biosystems®) and Power Sybr Green PCR Master mix (Applied Biosystems®) according to the 
manufacturer’s protocol. The region tested on mtDNA was included in the 12S gene (forward 
primer: CGCCAGAACACTACGA; reverse primer: AGGGTTTGCTGAAGAT) (10). The 
nuclear encoded 18S rRNA gene was used as endogenous reference (forward primer: 
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AAACGGCTACCACATCC; reverse primer: CCTCGAAAGAGTCCTG) (50). The level of 
mtDNA was calculated using the ΔCT of average CT of mtDNA and nDNA (ΔCT = CT nDNA - 
CT mtDNA) as 2ΔCT (10).  
 
Mitochondrial Surface Estimation. Representative pictures from ERCC1-WT (20 pictures) and 
ERCC1-KO (27 pictures) cells were taken with a SISMegaviewIII charge-coupled device camera 
(Olympus, Tokyo, Japan). Mean surface was calculated after manual delimitation of mitochondria 
from ERCC1-WT (n=87) and ERCC1-KO (n=122) cells. Student's t-test was used to determine 
the significance of the differences between the mean mitochondrial surfaces in both cell lines. 
 
Immunohistochemisty on tumor samples. Archival samples from resected lung adenocarcinoma 
(stage I, II and IIIA) were used. For each case, one representative formalin fixed paraffine 
embedded (FFPE) block was selected for the study. Automated immunohistochemistry was 
performed on 4 µm thick sections from FFPE tissue blocks using a Ventana Discovery Ultra 
platform (Roche Diagnostics®, Tucson, AZ). After deparaffinization and epitope retrieval (CC1 
buffer, 32 minutes), the slides were incubated with an anti-ERCC1 (clone SP68, Spring 
Bioscience®, 1:500 dilution) or an anti-NAMPT (clone 14A5, Merck Millipore, 1:1000 dilution) 
antibody during one hour at room temperature. Detection was performed with the UltraMap 
detection kit and diaminobenzidine as a chromogen. Pathological assessment of NAMPT and 
ERCC1 stainings were performed independently by a senior pathologist. ERCC1 
immunohistochemistry was scored as high or low based on the prominent intensity of staining 
observed for each case in the nuclei of tumor cells. Tumors with weak staining (0/1+) were scored 
as low and tumors with strong staining (2+/3+) was scored as high. Staining of intratumoral 
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lymphocytes was used as an internal positive control. Scoring was based on cytoplasmic staining 
for NAMPT using an H-score (staining intensity from 0 to 3+ mutiplied by percentage of positive 
cells).  
 
Apoptosis. Apoptosis was assessed through the detection of cell surface phosphatidylserine 
exposure, using phycoerythrin-conjugated annexin V staining (PE Annexin V Apoptosis Detection 
Kit, Becton Dickinson®) and flow cytometry analysis. Cells were cultured with vehicle or 2 and 
10 nM FK866, and collected following 5 days treatment. 5.105 cells were collected per sample, 
washed twice and resuspended in the provided binding buffer, containing 5% annexin V and 5% 
7-AAD. Detection was achieved using a fluorescent-activated cell sorter LSR-II flow cytometer 
(Becton Dickinson®), running FACS Diva software®. Data analysis were performed using 
FlowJo software®.  
 
ROS production. Dihydroethidium (DHE) fluorescence kinetics were measured using flow 
cytometry during 30 minutes without treatment and on FK866 at 2 nM. Antimycin, a complex III 
inhibitor that induces a major oxidative stress, was used as a positive control at 1 µM. Extracellular 
H2O2 production was measured using the Amplex red/horseradish peroxidase (HRP) assay. 
Amplex Red peroxidation was monitored continuously for 1 hour. All measurements were 
performed in triplicate.  
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Figure 1 – SILAC-based proteomic analysis identifies NAMPT decrease as a potentially targetable 
node in ERCC1-deficient clones. (A) Experimental workflow for the quantitative proteomic analysis 
using SILAC. Two independent experiments in the ERCC1-WT and ERCC1-KO cell lines from the A549 
model with inverted labeling of the cell lines (forward and reverse experiments) were set up and run in 
parallel in order to limit the number of false positive hits by having an internal control (n = 2 independent 
samples for each model). Protein lysates were mixed in a 1:1 proportion between the heavy- and light-
labeled cells. After protein digestion and off-gel fractionation, fractions were analyzed by LC-MS/MS, and 
final analysis of raw data was performed using Proteome Discoverer® v1.3 and Mascot v2.3, followed by 
protein identification using Scaffold v3.6.2. (B) Scatter plot of the ratio of heavy over low amino acids 
normalized to the reverse (R) or forward (F) experiment, following a Log2 normalization. Hits reaching 
significance (Bonferroni corrected P-value < 0.05) in both experiments are depicted in red. (C) Canonical 
NAD+ biosynthetic pathways. In humans, most NAD+ is synthesized from nicotinamide (NAm) through 
the salvage (recycling) pathway. NAMPT (NAm phosphoribosyltransferase) catalyzes the rate-limiting step 
in this pathway. Sirtuins (SIRTs) and poly(ADP-ribose) polymerase (PARPs) enzymes catalyze reactions 
that consume NAD+. Reaction scheme is based on the Biocyc pathway map for homo sapiens NAD+ 
biosynthesis (http://biocyc.org/), and adapted from Kim et al 15. NAPRT, nicotinic acid 
phosphoribosyltransferase; QPRT, quinolinic acid phosphoribosyltransferase; NMNATs, NMN 
adenylyltransferases; NADS, NAD+ synthetase. 
A B
C
	 43	
 
 
Figure 2 – ERCC1 expression correlates with NAMPT expression in human adenocarcinoma cell 
lines and patient samples. (A-B) Representative western blot of NAMPT and ERCC1 protein expression 
in the ERCC1-deficient isogenic models derived from the A549 (A) and H1975 (B) NSCLC cell lines. Data 
were replicated in three independent experiments. (C) NAMPT mRNA levels in ERCC1-WT, ERCC1-Hez 
and ERCC1-KO cell lines from the A549 model. Data are boxplots of NAMPT mRNA levels (± minimal 
and maximal values) with n = 4 independent experiments for each model. Statistical analyses are indicated 
(Kruskal-Wallis one-way ANOVA adjusted using Dunn's multiple comparison test). (D) ERCC1 and 
NAMPT immunohistochemical stainings in human adenocarcinoma samples. Data are boxplots (± minimal 
and maximal values) showing NAMPT protein expression according to ERCC1 expression in n = 55 tumor 
samples. Statistical analyses are indicated (Mann-Whitney test). (E) Representative images of ERCC1 and 
NAMPT immunohistochemical stainings in human tumor samples. 
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Figure 3 – NAMPT decrease in ERCC1-deficient clones leads to exquisite sensitivity to NAMPT 
inhibitors. (A) Chemical structures of NAMPT inhibitors FK866 and GNE-617. (B–C) Survival curves of 
the A549 ERCC1 isogenic model on FK866 exposure in short-term assay (B) and long-term colony 
formation assay (C). Data are mean surviving fractions ± SD from one of three independent experiments. 
(D) Representative pictures of the colony formation assay in the A549 ERCC1 isogenic model after 14 days 
of treatment with vehicle or FK866. (E) Representative western blot of PARP and LC3 protein expression 
in A549 ERCC1-proficient and ERCC1-deficient cells treated with vehicle or FK866. 
Thapsigargin (THAPS) was used as positive control for apoptosis and induction of autophagy. Data are 
from one experiment. (F) Fraction of Annexin V-positive (both 7-AAD-negative or 7-AAD-positive) cells 
determined by flow cytometry analysis after 5 days of exposure with FK866 in A549 ERCC1-proficient 
and ERCC1-deficient cells. Data are from one experiment. 
CA
FK866
GNE-617
D
E FERCC1-WT
EtOH THAPS FK86610nMEtOH THAPS
FK866
10nM
PARP
Cleaved PARP
Actin
110	kDa
90	kDa
ERCC1-KO
40	kDa
15	kDa
LC3-I
LC3-II
B
A
p
o
p
to
tic
 F
ra
ct
io
n
 (
%
to
ta
l c
e
lls
)
V e
h i
c l
e
F K
8 6
6  
2  
n M
F K
8 6
6  
1 0
 n
M
V e
h i
c l
e
F K
8 6
6  
2  
n M
F K
8 6
6  
1 0
 n
M
V e
h i
c l
e
F K
8 6
6  
2  
n M
F K
8 6
6  
1 0
 n
M
0
1 0
2 0
3 0
4 0
E R C C 1 -W T
E R C C 1 -H e z
E R C C 1 -K O
A 5 4 9
C lo n o g e n ic  s u rv iv a l (1 4  d a y s )
0 .0 1 0 .1 1 1 0
0 .0
0 .5
1 .0
F K -8 6 6  (n M )
S
u
rv
iv
in
g
 f
ra
c
ti
o
n
E R C C 1 -W T
ERCC 1 -H ez
E R CC 1 -KO
0
A 5 4 9
V ia b ility  a s s a y  (5  d a y s )
0 .0 1 0 .1 1 1 0 1 0 0
0 .0
0 .5
1 .0
E R C C 1 -W T
ER CC 1 -KO 1
F K -8 6 6  (n M )
S
u
rv
iv
in
g
 f
ra
c
ti
o
n
ERCC 1 -H ez
E R CC 1 -KO 2
A
p
o
p
to
tic
 F
ra
ct
io
n
 (
%
to
ta
l c
e
lls
)
V e
h i
c l
e
F K
8 6
6  
2  
n M
F K
8 6
6  
1 0
 n
M
V e
h i
c l
e
F K
8 6
6  
2  
n M
F K
8 6
6  
1 0
 n
M
V e
h i
c l
e
F K
8 6
6  
2  
n M
F K
8 6
6  
1 0
 n
M
0
1 0
2 0
3 0
4 0
E R C C 1 -W T
E R C C 1 -H e z
E R C C 1 -K O
Vehicle Vehicle
FK866 (nM) FK866 (n )
Su
rv
ivi
ng
 f
ra
ct
ion
Su
rv
ivi
ng
 f
ra
ct
ion
	 45	
 
 
Figure 4 – Exquisite sensitivity to NAMPT inhibition is a primary effect of ERCC1-deficiency. (A) 
Representative western blot of NAMPT and ERCC1 protein expression and (B) survival experiment on 
FK866 exposure according to the reintroduction of the four alternative ERCC1 isoforms. (C) Survival 
experiment on FK866 exposure of the H1975 ERCC1-isogenic model. (D) Survival experiment on GNE-
617 exposure of the A549 ERCC1-isogenic model. (E–F) Rescue of the FK866 toxicity by the 
administration of nicotinamide mononucleotide (NMN) 100 µM in the H1975 (E) and A549 (F) ERCC1-
isogenic models. For (B-F) data are mean surviving fraction ± SD from one experiment. (G) Cell viability 
after acute NAMPT silencing by siRNA in A549 ERCC1-proficient and ERCC1-deficient cells. Toxicity 
of PLK1 silencing by siRNA was used a positive control for cell death induction. Data are mean viability 
± SD from one experiment. Statistical analyses are indicated (Mann-Whitney test corrected for multiple 
comparisons). NS: no statistically significant difference. (H) Representative western blot of NAMPT and 
ERCC1 protein expression after NAMPT silencing by siRNA in A549 ERCC1-proficient and ERCC1-
deficient cells. For (A-H), data were replicated in at least three independent experiments. 
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Figure 5 – NAMPT inhibition is synthetic lethal with ERCC1-deficiency in in vivo models of NSCLC. 
(A) Experimental workflow for the in vivo experiments. Treatment was initiated when tumors reached a 
volume of 100mm3. Tumor-bearing mice (n = 8 per group) were randomized to receive FK866 30mg/kg/day 
FK866 or vehicle for 6 weeks following a 4-days on / 3-days off schedule. (B) Changes in tumor volume 
after 44 days of treatment with FK866 in ERCC1-proficient and ERCC1-deficient tumors in nude mice. 
Data are mean tumor volume ± SD (n = 8 mice per group). Statistical analyses are indicated (2-way 
ANOVA adjusted for multiple comparisons using Bonferroni’s test). (C–D) Tumor growth on FK866 
treatment in the A549 ERCC1-WT and ERCC1-KO1 models (C), and in the ERCC1-KO2 model (D). Data 
represent mean tumor volume ± SEM (n = 8 mice per group). Statistical analyses are indicated (2-way 
ANOVA adjusted for multiple comparisons using Bonferroni’s test). *: P < 0.05, **: P < 0.01, ***: P < 
0.0001.  
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Figure 6 – ERCC1-deficient cells present a characteristic metabolic profile with alterations in the 
NAD+ biosynthesis pathway. (A) Heatmap depicting relative abundances of 159 metabolites (annotation 
level 1, see material and methods) determined by metabolomic profiling in the ERCC1-WT (n = 5 
independent samples), ERCC1-Hez (n = 3) and ERCC1-KO (n = 3) cell lines from the A549 model. 
Samples (rows) and metabolites (columns) were re-ordered by hierarchical clustering using the Ward 
algorithm on their respective Euclidean distance matrices. (B) Box plots showing the relative abundance of 
central metabolites of the NAD+ pathway (NAD+, NADH, NADP, and nicotinamide) across the ERCC1-
WT (n = 5 independent samples), ERCC1-Hez (n = 3) and ERCC1-KO (n = 3) cell lines with and without 
treatment by FK866. Data were centered on the ERCC1-WT vehicle group for comparative purposes. All 
statistical analyses and data representation were performed on pre-processed, log2-transformed and 
imputed data and reported as such without back-transformation. Moderated statistics were used for 
differential analysis 48. Levels of significance were denoted as P-values adjusted according to Benjamini 
and Hochberg 49 to control the false discovery rate (FDR).  
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Figure 7 – ERCC1-deficient cells present abnormal mitochondrial structure associated with 
decreased respiratory capacity and increased glycolysis. (A) Representative transmission electron 
microscopy (TEM) pictures of the A549 ERCC1-WT, ERCC1-Hez and ERCC1-KO cell lines. m, 
mitochondria. Scale bars: 1 µm. (B) Measurements of mitochondrial area using TEM in A549 ERCC1-
deficient and ERCC1-proficient cells. Data are boxplots (± minimal and maximal values) from n = 87-122 
mitochondria per group. Statistical analyses are indicated (Mann Withney test). (C–D) OCR (oxygen 
consumption rate) and ECAR (extracellular acidification rate) of intact A549 ERCC1-WT, ERCC1-Hez 
and ERCC1-KO cells measured in real time in the Seahorse XF96 analyzer® (Agilent). Indices of 
glycolysis and mitochondrial function were measured after sequential injections of oligomycin (1µg/ml 
final), CCCP (first 0.25 µM then 0.50 µM) and antimycin A (1µg/ml). Data are mean ± SD from one 
experiment. For (A-D), data were replicated in three independent experiments. 
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Figure 8 – ERCC1-KO cells have a decreased mitochondrial complex IV activity associated with 
decreased SIRT1 protein expression. Representative western blot (A) and quantification (B) of COX2 
and COX4 protein expression in A549 ERCC1-proficient and ERCC1-deficient cell lines. Data were 
replicated in three independent experiments. (C) Enzymatic activities of mitochondrial complexes 
measured using respiratory chain spectrophotometric assay in A549 ERCC1-proficient and ERCC1-
deficient cell lines (n = 3 independent samples per group). Data are mean enzymatic activity ± SD. 
Statistical analyses are indicated (two-way ANOVA adjusted using Tukey’s multiple comparison test). NS: 
no statistically significant difference, ***: P < 0.0001. (D) Enzymatic activity of mitochondrial complex 
IV in A549 ERCC1-proficient and ERCC1-deficient models in which each ERCC1 isoform has been stably 
reintroduced. Data are from one experiment. (E) Western blot of NAMPT and SIRT1 protein expression in 
A549 ERCC1-WT, ERCC1-Hez and ERCC1-KO cells. Data are from one experiment. 
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Figure 9 – Loss of ERCC1 results in increased ADP-ribosylation and gradual decrease in NAMPT 
expression. (A) ADP-ribosylation levels were measured by immunofluorescence in A549 cells not treated 
(NT) or treated with control (scramble siRNA) or ERCC1 siRNA (si-ERCC1). H2O2 exposure was used 
for inducing DNA damage. Olaparib was used as control for abrogation of PARP1-related ADP-
ribosylation activity. Data are mean ADP-ribosylation activity ± SD from one of three independent 
experiments. (B) Representative western Blot of ERCC1 and NAMPT protein expression after acute 
ERCC1 silencing using siRNA in A549 cells. NT: non-transfected. Data were replicated in two independent 
experiments. (C) Western Blot of ERCC1 and NAMPT protein expression after sequential transfections 
with shERCC1-coding viral particles in A549 cells. V1, V2, V3: infections 1, 2 and 3, respectively, which 
were performed 10-15 days apart each. Data are from one experiment. (D-E) ADP-ribosylation levels were 
measured by immunofluorescence in A549 isogenic model in absence (D) or presence (E) of NMN 
supplementation. Data are mean ADP-ribosylation activity ± SD from one of two independent experiments. 
(F) Variations in NAMPT mRNA levels in A549 ERCC1-WT, ERCC1-Hez and ERCC1-KO cell lines 
following 3-day exposure to non-toxic concentrations the SIRT1 activator STR2104. Data represents mean 
2-ΔΔCt ± SD from one experiment. Statistical analyses are indicated (two-way ANOVA adjusted using Sidak 
multiple comparison test). (G) Representative western blot of NAMPT protein expression after 4-day 
exposure to non-toxic concentrations of STR2104. Data were replicated in two independent experiments. 
For (A, D, E), statistical analyses are indicated (two-way ANOVA adjusted for multiple comparisons using 
Tukey’s test).   
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Figure 10 – Proposed model for the synthetic lethality between NAMPT inhibition and ERCC1-
deficiency in NSCLC cells. (A) ERCC1 proficient cells have a proficient DNA damage repair status and 
no metabolic alteration in the NAD+ biosynthesis pathway. (B) Loss of ERCC1 induces decreased NER 
activity and dependency upon PARP1 activation for the repair of DNA lesions, thereby causing NAD+ 
consumption. Chronic ERCC1 deficiency associates with metabolic defects including decreased NAD+ and 
NAMPT levels, as well as alterations in the mitochondrial respiratory chain. In this scenario, NAD+ levels 
are low but remain above a threshold allowing ERCC1-deficient cells to survive and proliferate. (C) 
Treatment with NAMPT inhibitors block the NAD+ recycling pathway and cause an acute drop in NAD+ 
levels. In ERCC1-proficient cells, NAD+ levels remain above a critical threshold compatible with cell 
survival. In ERCC1-deficient cells, this acute NAD+ drop outstrips the cellular NAD+ replenishment 
capacities and decompensates a fragile equilibrium; NAD+ levels drop below a threshold compatible with 
cell survival, which triggers cell death. In this model, NAMPT and ERCC1 are synthetic lethal, as the 
combination of ERCC1-deficiency to NAMPT inhibition causes cell death, whereas each perturbation in 
isolation (i.e. ERCC1-deficiency or NAMPT inhibition) does not. Arrows represent a relationship and not 
a demonstrated causality link. Abbreviations: DDR: DNA damage response; ERCC1-def: ERCC1-
deficient; NER: Nucleotide Excision Repair; WT: wild-type.  
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Supplementary Figure 1 – Western blot of NAMPT protein expression in A549 ERCC1-WT, ERCC1-
Hez and ERCC1-KO cells. Top: control. Bottom: bortezomib exposure (48h of treatment at the IC20). 
Data are from one experiment.  
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Supplementary Figure 2 – Representative images of ERCC1 staining and scoring. Scale bars: 50 µM. 
Data are from one representative experiment (n = 55 total tumor samples analyzed). 
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Supplementary Figure 3 – Apoptosis induction by FK866 in A549 ERCC1-proficient and ERCC1-
deficient cell lines. Cells were treated with either vehicle or FK866 (2 nM and 10 nM), cultured for 3 days 
(A-B) or 5 days (C) and then stained with a combination of Annexin V and 7-AAD. (A) Fraction of Annexin 
V-positive cells after 3 days of treatment with FK866 in A549 ERCC1-proficient and ERCC1-deficient 
cells. (B-C) Dot plots of flow cytometric analysis from cells stained with AnnexinV (horizontal axis) and 
7-AAD (vertical axis) after 3 (B) or 5 days (C) of FK866 exposure. Data are from one experiment 
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Supplementary Figure 4 – Exquisite sensitivity to NAMPT inhibition is a primary effect of ERCC1-
deficiency. (A) Survival experiment on FK866 (left) and CDDP (right) of the A549 ERCC1-isogenic 
model. (B) Representative western blot of ERCC1 protein expression in the ERCC1 non-isogenic NSCLC 
models. Data are from one experiment. (C) Survival curves assessing sensitivity to FK866 assessed by 
short-term assay in the ERCC1 non-isogenic NSCLC models. Data are from one representative experiment. 
(D) Rescue of the GNE-617 toxicity by the administration of nicotinamide mononucleotide (NMN) 100 
µM in A549 cells. For (A,C,D) data represents mean surviving fraction ± SEM from one of three 
independent experiments.  
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Supplementary Figure 5 – In vivo supplementary data. (A-C) Mice weights during treatment with 
vehicle or FK866, in groups injected with the ERCC1-WT cells (A) and ERCC1-KO isogenic cell lines (B-
C). Data are mean ± SD with n = 8 mice in each group.  
  
0 10 20 30 40 50
25
30
35
Treatment time (days)
M
ic
e 
w
ei
gh
t (
g)
ERCC1-KO1 Vehicle
FK866
B
0 10 20 30 40 50
25
30
35
Treatment time (days)
M
ic
e 
w
ei
gh
t (
g)
ERCC1-KO2 Vehicle
FK866
ERCC1-WT
0 10 20 30 40 50
25
30
35
Treatment time (days)
M
ic
e 
w
ei
gh
t (
g)
FK866
Vehicle
A
C
	 57	
 
 
 
Supplementary Figure 6 – Supplementary metabolomic data (1). (A) Distribution of the relative 
abundancies of citrate/isocitrate, 2-oxoglutarate, succinate and fumarate across the ERCC1-WT (n = 5 
independent samples), ERCC1-Hez (n = 3) and ERCC1-KO (n = 3) cell lines treated with FK866 or vehicle. 
(B) Measurements of succinate (i), fumarate (ii) and methylmalonic acid levels (iii) levels following 
inhibition of the succinate dehydrogenase by 24h treatment with methylmalonic acid in A549 ERCC1-
proficient and ERCC1-deficient cell lines. Abbreviations: NS, not significant; ***, P < 0.01. (C) 
Distribution of the relative abundancies of C18:1, C14:1, C8:0 and C6:0 acylcarnitines across the ERCC1-
WT, ERCC1-Hez and two ERCC1-KO cell lines treated by vehicle. For (A-C) statistical analyses and data 
representation were performed on pre-processed, log2-transformed and imputed data and reported as such 
without back-transformation. Moderated statistics were used for differential analysis. Moderated statistics 
were used for differential analysis 48. Levels of significance were denoted as P-values adjusted according 
to Benjamini and Hochberg 49 to control the false discovery rate (FDR). 
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Supplementary Figure 7 – Supplementary metabolomic data (2). (A) Relative distribution of 
metabolites in the ERCC1-Hez (n = 3 independent samples) and two ERCC1-KO (n = 3 per group) cell 
lines treated by vehicle (top) or FK866 (bottom). Metabolites at FDR < 0.1 (Benjamini and Hochberg) are 
depicted. Selected metabolites from the NAD biosynthesis pathway are highlighted. (B) Distribution of the 
relative abundancies of ATP, ATP/ADP and ATP/AMP ratios across the ERCC1-WT (n = 5 independent 
samples), ERCC1-Hez (n = 3) and ERCC1-KO (n = 3) cell lines treated with FK866 or vehicle. Data were 
centered on the ERCC1-WT vehicle group for comparative purposes. For (A-B) statistical analyses and 
data representation were performed on pre-processed, log2-transformed and imputed data and reported as 
such without back-transformation. Moderated statistics were used for differential analysis 48. Levels of 
significance were denoted as P-values adjusted according to Benjamini and Hochberg 49 to control the false 
discovery rate (FDR). 
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Supplementary Figure 8 – ERCC1 deficiency associates with decreased respiratory capacity. (A–B) 
Relative basal (A) and maximal (B) mitochondrial respiratory capacity of intact A549 ERCC1-WT, 
ERCC1-Hez and ERCC1-KO cell lines measured in real time with high-resolution respirometry 
(Oroboros). Data represents mean respiration capacity ± SD normalized to the ERCC1-WT group with n = 
3 independent samples per group. Statistical analyses are indicated (one-way ANOVA adjusted for multiple 
comparisons).  
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Supplementary Figure 9 – ERCC1-deficient cells do not have increased ROS levels. (A) Reactive 
oxygen species (ROS) kinetics were measured using the kinetics of dihydroethidium (DHE) fluorescence 
in A549 ERCC1-proficient and ERCC1-deficient cell lines. Data represent mean DHE slope ± SD from 
two independent experiments. Statistical analyses are indicated (Friedman test adjusted for multiple 
comparisons using Dunn’s test). NS: no statistically significant difference. (B) Extracellular H2O2 kinetics 
in ERCC1-proficient and ERCC1-deficient models. Data represent mean ± SD from one of two independent 
experiment. Statistical analyses are indicated (linear regression analysis). (C) Western blot of carbonyl 
adducts in A549 ERCC1-proficient and ERCC1-deficient cell lines (Oxyblot procedure). Each sample is 
followed by its replicate without DNPH derivation as negative control. DNP: dinitrophenyl hydrazone 
adducts, DNPH: 2,4-dinitrophenylhydrazine. (D) Quantification of carbonyls adducts measured by western 
blot in A549 ERCC1-proficient and ERCC1-deficient cell lines. (E) Western blot of HNE adducts in A549 
ERCC1-proficient and ERCC1-deficient cell lines. HNE: 4-Hydroxynonenal. (F) Quantification of HNE 
adducts measured by western blot in A549 ERCC1-proficient and ERCC1-deficient cell lines. (G) Western 
blot of SOD1, SOD2 and PRDX3 protein expression in A549 ERCC1-proficient and ERCC1-deficient cell 
lines. SOD1: superoxide dismutase 1, SOD2: superoxide dismutase 2, PRDX3: peroxiredoxine 3. For (C-
G), data are from one experiment. 
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Supplementary Figure 10 – ERCC1 deficiency associates with decreased mitochondrial biogenesis. 
Relative mitochondrial DNA (mtDNA) copy number in A549 ERCC1-WT, ERCC1-Hez, ERCC1-KO, and 
ERCC1-rescued (isoforms 201 to 204) cell lines. Values were normalized to ERCC1-WT cells. Statistical 
analyses are indicated (one-way ANOVA adjusted for multiple comparisons). Only statistically significant 
differences are depicted, all other P-values are not significant. Data are from two independent experiments. 
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